Insta
DCGI's Expert Panel To Take Up Zydus Cadila's Application For Emergency Use Approval To Its COVID-19 Jab This Week: Report
ZyCov-D
The subject expert committee (SEC) of the Indian Drug Regulator is likely to take up Ahmedabad-based pharmaceutical major Zydus Cadila's application for emergency use approval to its Covid-19 vaccine this week.
Zydus had last week approached the Drug Controller General of India (DCGI) for emergency use approval to its three-dose Covid-19 vaccine ZyCoV-D.
“The rolling review has been done and now it will be put up before the SEC for its recommendations,” a senior government was quoted by Economic Times as saying.
“The meeting is likely to happen sometime this week," the official added.
The vaccine, if approved by the DCGI, will be the fifth vaccine to get Indian drug regulator's nod for use in India. The DCGI had earlier approved Serum Institute of India's Covishield, Bharat Biotech's Covaxin, Russian Covid-19 vaccine Sputnik V and US-based Moderna's Covid jab.
Zydus developed the DNA based vaccine with the support of the Central government's Department of Biotechnology and the Indian Council of Medical Research (ICMR). The jab has shown 66.6 per cent efficacy in an interim study.
Introducing ElectionsHQ + 50 Ground Reports Project
The 2024 elections might seem easy to guess, but there are some important questions that shouldn't be missed.
Do freebies still sway voters? Do people prioritise infrastructure when voting? How will Punjab vote?
The answers to these questions provide great insights into where we, as a country, are headed in the years to come.
Swarajya is starting a project with an aim to do 50 solid ground stories and a smart commentary service on WhatsApp, a one-of-a-kind. We'd love your support during this election season.
Click below to contribute.
Latest
